140 related articles for article (PubMed ID: 15223243)
1. Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment.
Maiti PK; Feferman T; Im SH; Souroujon MC; Fuchs S
J Neuroimmunol; 2004 Jul; 152(1-2):112-20. PubMed ID: 15223243
[TBL] [Abstract][Full Text] [Related]
2. Induction of interferon-gamma, interleukin-4, and transforming growth factor-beta in rats orally tolerized against experimental autoimmune myasthenia gravis.
Wang ZY; Link H; Ljungdahl A; Höjeberg B; Link J; He B; Qiao J; Melms A; Olsson T
Cell Immunol; 1994 Sep; 157(2):353-68. PubMed ID: 7520837
[TBL] [Abstract][Full Text] [Related]
3. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.
Yi HJ; Chae CS; So JS; Tzartos SJ; Souroujon MC; Fuchs S; Im SH
Mol Immunol; 2008 Nov; 46(1):192-201. PubMed ID: 18799218
[TBL] [Abstract][Full Text] [Related]
4. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis.
Wang HB; Shi FD; Li H; van der Meide PH; Ljunggren HG; Link H
Clin Immunol; 2000 May; 95(2):156-62. PubMed ID: 10779409
[TBL] [Abstract][Full Text] [Related]
5. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment.
Im SH; Barchan D; Fuchs S; Souroujon MC
J Clin Invest; 1999 Dec; 104(12):1723-30. PubMed ID: 10606626
[TBL] [Abstract][Full Text] [Related]
6. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.
Duan RS; Adikari SB; Huang YM; Link H; Xiao BG
Neurobiol Dis; 2004 Jul; 16(2):461-7. PubMed ID: 15193302
[TBL] [Abstract][Full Text] [Related]
7. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18.
Im SH; Barchan D; Maiti PK; Raveh L; Souroujon MC; Fuchs S
FASEB J; 2001 Oct; 15(12):2140-8. PubMed ID: 11641240
[TBL] [Abstract][Full Text] [Related]
8. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.
Xiao BG; Duan RS; Zhu WH; Lu CZ
Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165
[TBL] [Abstract][Full Text] [Related]
9. Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats.
Saoudi A; Bernard I; Hoedemaekers A; Cautain B; Martinez K; Druet P; De Baets M; Guéry JC
J Immunol; 1999 Jun; 162(12):7189-97. PubMed ID: 10358165
[TBL] [Abstract][Full Text] [Related]
10. Suppression of myasthenia gravis by antigen-specific mucosal tolerance and modulation of cytokines and costimulatory factors.
Souroujon MC; Maiti PK; Feferman T; Im SH; Raveh L; Fuchs S
Ann N Y Acad Sci; 2003 Sep; 998():533-6. PubMed ID: 14592924
[TBL] [Abstract][Full Text] [Related]
11. Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis.
Im SH; Barchan D; Souroujon MC; Fuchs S
J Immunol; 2000 Oct; 165(7):3599-605. PubMed ID: 11034361
[TBL] [Abstract][Full Text] [Related]
12. Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T cells.
Xu L; Villain M; Galin FS; Araga S; Blalock JE
Cell Immunol; 2001 Mar; 208(2):107-14. PubMed ID: 11333143
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis.
Im SH; Barchan D; Fuchs S; Souroujon MC
J Neuroimmunol; 2000 Nov; 111(1-2):161-8. PubMed ID: 11063834
[TBL] [Abstract][Full Text] [Related]
14. Animal models of myasthenia gravis.
Christadoss P; Poussin M; Deng C
Clin Immunol; 2000 Feb; 94(2):75-87. PubMed ID: 10637092
[TBL] [Abstract][Full Text] [Related]
15. Lack of pathogenicity of immunodominant T and B cell determinants of the nicotinic acetylcholine receptor epsilon-chain.
Gaertner S; de Graaf KL; Wienhold W; Wiesmüller KH; Melms A; Weissert R
J Neuroimmunol; 2004 Jul; 152(1-2):44-56. PubMed ID: 15223236
[TBL] [Abstract][Full Text] [Related]
16. Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice.
Paas-Rozner M; Dayan M; Paas Y; Changeux JP; Wirguin I; Sela M; Mozes E
Proc Natl Acad Sci U S A; 2000 Feb; 97(5):2168-73. PubMed ID: 10681457
[TBL] [Abstract][Full Text] [Related]
17. Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): induction of protective tolerance in primed animals.
Shi FD; Bai XF; Li HL; Huang YM; Van der Meide PH; Link H
Clin Exp Immunol; 1998 Mar; 111(3):506-12. PubMed ID: 9528890
[TBL] [Abstract][Full Text] [Related]
18. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4.
Im SH; Barchan D; Maiti PK; Fuchs S; Souroujon MC
J Immunol; 2001 Jun; 166(11):6893-8. PubMed ID: 11359850
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulin suppresses experimental myasthenia gravis: immunological mechanisms.
Zhu KY; Feferman T; Maiti PK; Souroujon MC; Fuchs S
J Neuroimmunol; 2006 Jul; 176(1-2):187-97. PubMed ID: 16730380
[TBL] [Abstract][Full Text] [Related]
20. Mucosal tolerance to experimental autoimmune myasthenia gravis is associated with down-regulation of AChR-specific IFN-gamma-expressing Th1-like cells and up-regulation of TGF-beta mRNA in mononuclear cells.
Ma CG; Zhang GX; Xiao BG; Wang ZY; Link J; Olsson T; Link H
Ann N Y Acad Sci; 1996 Feb; 778():273-87. PubMed ID: 8610980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
